

Subt. For, PTO-1449

**INFORMATION DISCLOSURE
IN AN APPLICATION**
(Use several sheets if necessary)Docket Numbers
**112418.151US2 and
AUR-016US**Application Number
10/801,988Applicant(s)
Georges et al.Filing Date
December 15, 2003Group Art Unit
1614

Sheet 1 1

U.S. Patent Documents

Examiner Initial	Document Number	Publn. Date mm-dd-yyyy	Name Of Patentee Or Applicant Of Cited Documents	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

Foreign Patent Documents

Examiner Initial	Cite No.	Foreign Patent Document	Publn. Date mm-dd-yyyy	Country	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code-Number-Kind			
CF		DE 41 12999 A1	10/22/1992	DE	
		WO 02/082076 A2	10/17/2002	WIPO	

Examiner's Initial	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)	
CF	AA	BICHART, F., et al., "Cytoskeleton Alteration in MCF7R Cells, a Multidrug Resistant Human Breast Cancer Cell Line," <i>Anticancer Research</i> , Vol. 17, pp. 3393-3402.
	AB	Database Pubmed [Online], "Triosephosphate Isomerase," US National Library of Medicine, XP002301823, Bethesda, MD, 5 January 2001.
	AC	LUDWIG, A., et al., "Identification of Differential Expressed Genes in Classical and Atypical Multidrug-resistant Gastric Carcinoma Cells," <i>Anticancer Research</i> , Vol.17, pp. 3213-3222, 1997.
	AD	MORAN E., et al., "Co-expression of MDR-Associated Markers, Including P-170, MRP and LRP and Cytoskeletal Proteins, in Three Resistant Variants of the Human Ovarian Carcinoma Cell Line, OAW42," <i>Eur J. Cancer</i> , Vol. 33, pp. 652-660, 1997.
	AE	SEKIGUCHI, M., et al., "Biological Characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines," <i>Biomed. Pharmacother</i> , Vol. 55, pp.466-474, 2001.
	AF	SWEET, P., et al., "Cyclosporin A and Verapamil Enhancement of Daunorubicin-produced Nucleolar Protein B23 Translocation in Daunorubicin-resistant and -sensitive Human and Murine Tumor Cells," <i>Cancer Research</i> , Vol. 49, pp. 677-680, 1989.
	AG	YANG, W., et al., "Multi-epitope schistosome vaccine candidates tested for protective immunogenicity in mice," <i>Vaccine</i> , Vol. 19, pp. 103-113, 2001.

EXAMINER <i>Cathleen [Signature]</i>	DATE CONSIDERED <i>7/20/06</i>
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/801,988
				Filing Date	March 15, 2004
				First Named Inventor	GEORGES et al.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AUR-016US /112418.151US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CA	AA*	US-4,444,744	04-24-1984	Goldenberg, Milton	
	AB*	US-5,762,930	06-09-1998	Fanger et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ³
ca	CA	BICHART et al. Cytoskeleton alteration in MCF7R, a multidrug resistant human breast cancer cell line., <i>Anticancer Res.</i> , 1997, pp. 3393-401, Vol. 17.			
	CB	ESSA et al. Vimentin expression in different types of breast carinorm aimmunohistochemical study, <i>J. Egypt Soc. Parasitol.</i> , 1996, pp. 433-42, Vol. 26.			
	CC	HEIDENTHAL et al. The Binding in Vitro of Modified LDL to the Intermediate Filament Protein Vimentin, <i>Biochemical and Biophysical Research Communications</i> , 2000, pp. 49-53, Vol. 267.			
	CD	MESCHINI et al. Intracellular P-Glycoprotein Expression is Associated with the Intrinsic Multidrug Resistance Phenotype in Human Colon Adenocarcinoma Cells. <i>Int. J. Cancer</i> , (2000), pp. 615-628, Vol. 87.			
	CE	THOMAS et al., Association between Keratin and Vimentin Expression, Malignant Phenotype and Survival in Postmenopausal Breast Cancer Patients, Oct. 1999, pp. 2698-2703, Vol. 5.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Catherine Jones</i>	Date Considered	7/20/06
-----------------------	------------------------	--------------------	---------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/801988-Conf. #2507		
		Filing Date	March 15, 2004		
		First Named Inventor	Elias GEORGES		
		Art Unit	1642		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	0112418.00151US2/AUR-016US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CP	CA	DERMER, BioTechnology, 1994, 12:320.	
	CB	DREXLER et al., Leukemia and Lymphoma, 1993, 9:1-25.	
	CC	FRESHNEY, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc. 1983, New York, p4.	
	CD	TOCKMAN et al., Cancer Research, 1992, 52:2711s-2718s.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	7/20/06
-----------------------	--	--------------------	---------



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 9 Application Number 10/801,988 Filing Date 03/15/2004 First Named Inventor Georges et al. Art Unit 1614 Examiner Name TBA Attorney Docket Number 112418-151/AUR-016

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CJ		US- 4,720,386	01/19/1988	McColleston	
		US- 5,194,384	03/16/1993	Bystryn	
		US- 5,407,653	04/18/1995	Piwnica-Worms	
		US- 6,338,853 B1	01/15/2002	Bystryn	
		US- 6,352,996 B1	03/05/2002	Cao et al.	
		US- 6,406,689 B1	06/18/2002	Falkenberg et al.	
		US- 6,417,336	07/09/2002	Morishima et al.	
		US- 6,476,193	11/05/2002	Nandabalan et al.	
		US- 6,511,676 B1	01/28/2003	Boulikas	
		US- 6,562,347 B1	05/13/2003	Kwak et al.	
		US- 6,572,856 B1	06/03/2003	Taylor et al.	
		US- 6,593,087 B2	07/15/2003	Prichard et al.	
		US- 6,623,923 B1	09/23/2003	Xu et al.	
		US- 6,630,327 B1	10/07/2003	Mechetner et al.	
		US- 6,657,048 B2	12/02/2003	Young et al.	
		US- 20020061316A1	05/23/2002	Srivastava	
		US- 20020198139A1	12/26/2002	Deutschman et al.	
		US- 20030012793A1	01/16/2003	Srivastava et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner Signature	Cathy [Signature]	Date Considered	7/20/06
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/801,988
		Filing Date	03/15/2004
		First Named Inventor	Georges et al.
		Art Unit	1614
		Examiner Name	TBA
Sheet 2 of 9	Attorney Docket Number	112418.151/AUR-016	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CJ		US- 20030012794A1	01/16/2003	Srivastava et al.	
		US- 20030031661A1	02/13/2003	Graner et al.	
		US- 20030087412A1	05/08/2003	Nandabalan et al.	
		US- 20030157081A1	08/21/2003	Bonini et al.	
		US- 20030165519A1	09/04/2003	Srivastava	
		US- 20030180721A1	09/25/2003	Witkin	
		US- 10/737,712	12/15/2003	Georges et al.	
		US- 10/736,889	12/15/2003	Georges et al.	
		US- 20040185511A1	09/23/2004	Georges et al.	
		US- 5,801,154	09/01/1998	Frank et al.	
		US- 2002110912A1	08/15/2002	Jatinder et al.	
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
CJ		WO 02/071061A	09/12/2002	Gabor et al.		
		WO 03/008542A	01/30/2003	Scherf et al.		
		EP 0813872A	12/29/1997	Kureha Chemical		

Examiner Signature: <i>Catherine D...</i>	Date Considered: 7/20/06
---	--------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/801,988
		Filing Date	03/15/2004
		First Named Inventor	Georges, et al.
		Art Unit	1614
		Examiner Name	TBA
Sheet 3 of 9	Attorney Docket Number	112418.151/AUR-016	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CJ		ABOU-JAWDE et al., An Overview of Targeted Treatments in Cancer, Clinical Therapeutics, Vol. 25, No. 8, 2003, pp. 2121-2137	
		ALQAWI and GEORGES, The multidrug resistance protein ABCC1 drug-binding domains show selective sensitivity to mild detergents, Biochemical and Biophysical Research Communications 303, 2003, pp. 1135-1141	
		BARRETO et al., Stress-induced release of HSC70 from human tumors, Cellular Immunology 222, 2003, pp. 97-104	
		CHENG et al., Retaining of the Assembly Capability of Vimentin Phosphorylated by Mitogen-Activated Protein Kinase-Activated Protein Kinase-2, Journal of Cellular Biochemistry, 89, 2003, pp. 589-602	
		DEN BOER et al., Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia, Blood, Vol. 91, No. 6, 1998, pp. 2092-2098	
		DI PIETRO et al., Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters, Cell. Mol. Life Sci. 59, 2002, pp. 307-322	
		DU et al., Dual Requirement for Rho and Protein Kinase C in Direct Activation of Phospholipase D1 Through G Protein-coupled Receptor Signaling, Molecular Biology of the Cell, Vol. 11, 2000, pp. 4359-4368	
		DURBIN et al., An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3, Proc. Natl. Acad. Sci. USA, Vol. 91, 1994, pp. 4313-4317	
		FAIGLE et al., Vimentin Filaments in Fibroblasts Are a Reservoir for SNAP23, a Component of the Membrane Fusion Machinery, Molecular Biology of the Cell, Vol. 11, 2000, pp. 3485-3494	
		FEIG, Designer Drugs: New Directed Therapies for Cancer, International Journal of Hematology Suppl. II, 76, 2002, pp. 281-283	

Examiner Signature	<i>Catherine [Signature]</i>	Date Considered	7/20/06
--------------------	------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/801,988
		Filing Date	03/15/2004
		First Named Inventor	Georges et al
		Art Unit	1614
		Examiner Name	TBA
Sheet 4 of 9	Attorney Docket Number	112418.151/AUR-016	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CJ		FUJITA et al., High Molecular Weight Vimentin Complex Is Formed after Proteolytic Digestion of Vimentin by Caspase-3: Detection by Sera of Patients with Interstitial Pneumonia, Microbiol. Immunol., 47(6), 2003, pp. 447-451	
		GARNETT, Targeted drug conjugates: principles and progress, Advanced Drug Delivery Reviews, 53, 2001, pp. 171-216	
		GOTO et al., Phosphorylation and reorganization of vimentin by p21-activated kinase (PAK), Genes to Cells, 7, 2002, pp. 91-97	
		GRATAMA et al., Flow Cytometric Quantitation of Immunofluorescence Intensity: Problems and Perspectives, Cytometry 33, 1998, pp. 166-178	
		HEIDENTHAL et al., The Binding in Vitro of Modified LDL to the Intermediate Filament Protein Vimentin, Biochemical and Biophysical Research Communications, 267, 2000, pp. 49-53	
		HERRMANN and AEBI, Intermediate filaments and their associates: multi-talented structural elements specifying cytoarchitecture and cytodynamics, Current Opinion in Cell Biology, 12, 2000, pp. 79-90	
		HUBERT et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors, PNAS, Vol. 96, No. 25, 1999, pp. 14523-14528	
		IQBAL and LENZ, Targeted Therapy and Pharmacogenomic Programs, Cancer Supplement, Vol. 97, No. 8, 2003, pp. 2076-2082	
✓		KIM et al., Multidrug Resistance-Associated Protein (MRP) is expressed in osteosarcoma but is not a significant mechanism of drug resistance, 47th Ann. Mtg., Orthopaedic Research Society, 2001, p. 0855	
		KIM, Targeted therapies for the treatment of cancer, The American Journal of Surgery, 186, 2003, pp. 264-268	

Examiner Signature	<i>[Signature]</i>	Date Considered	7/20/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/801,988
				Filing Date	03/15/2004
				First Named Inventor	Georges et al
				Art Unit	1614
				Examiner Name	TBA
				Attorney Docket Number	112418.151/AUR-016
Sheet	5	of	9		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
CD		KOWN et al., In Vivo Imaging of Acute Cardiac Rejection in Human Patients Using 99m Technetium Labeled Annexin V, American Journal of Transplantation, 1, 2001, pp. 270-277
		KREITMAN and PASTAN, Immunotoxins for targeted cancer therapy, Advanced Drug Delivery Reviews, 31, 1998, pp. 53-88
		LING, Multidrug resistance: molecular mechanisms and clinical relevance, Cancer Chemother. Pharmacol., 40 Suppl., 1997, pp. S3-S8
		MESCHINI et al., Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells, Int. J. Cancer, 87, 2000, pp. 615-628
		MOR-VAKNIN et al., Vimentin is secreted by activated macrophages, Nature Cell Biology, Vol, 5, 2003, pp. 59-63
		PARK, Tumor-directed Targeting of Liposomes, Bioscience Reports., Vol. 22, No. 2, 2002, pp. 267-281
		PATTERSON et al., Reduced Numatrin/B23/Nucleophosmin Labeling in Apoptotic Jurkat T-lymphoblasts, The Journal of Biological Chemistry, Vol, 270, No. 16, 1995, pp. 9429-9436
		ROTS et al., Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors, Journal of Controlled Release, 87, 2003, pp. 159-165
		ROWLINSON-BUSZA and EPEKETOS, Targeted delivery of biologic and other antineoplastic agents, Current Opinion in Oncology, 4, 1992, 1142-1148
		SCHROEIJERS et al., the Mr 193,000 Vault Protein Is Up-Regulated in Multidrug-resistant Cancer Cell Lines, Cancer Research, 60, 2000, pp. 1104-1110

Examiner Signature	<i>Catharine [Signature]</i>	Date Considered	7/20/06
-----------------------	------------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete, if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/801,988
		Filing Date	03/15/2004
		First Named Inventor	Georges et al.
		Art Unit	1614
		Examiner Name	TBA
Sheet 6 of 9	Attorney Docket Number	112418.151/AUR-016	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CJ ↓		WEHNER et al., Expression levels of hsc70 and hsp60 are developmentally regulated during B-cell maturation and not associated to childhood c-ALL at presentation or relapse, Eur. J. Haematol., 71, 2003, pp. 100-108	
		STEINERT et al., A High Molecular Weight Intermediate Filament-associated Protein in BHK-21 Cells Is Nestin, a Type VI Intermediate Filament Protein, The Journal of Biological Chemistry, Vol. 274, No. 14, 1999, pp. 9881-9890	
		STRELKOV et al., Molecular architecture of intermediate filaments, BioEssays, 25, 2003, pp. 243-251	
		TRAIL et al., Monoclonal antibody drug immunoconjugates for targeted treatment of cancer, Cancer Immunol. Immunother., 52, 2003, pp. 328-337	
		TREIB and KOTZ, Proteins expressed in osteosarcoma and serum levels as prognostic factors, The International Journal of Biochemistry & Cell Biology, 33, 2001, pp. 11-17	
		TUROWSKI et al., Vimentin Dephosphorylation by Protein Phosphatase 2A Is Modulated by the Targeting Subunit B55, Molecular Biology of the Cell, Vol. 10, 1999, pp. 1997-2015	
		WANG and LIU, Targeting Strategies in Cancer Gene Therapy, Acta Biochimica et Biophysica Sinica, 35(4), 2003, pp. 311-316	
		YOKOTA et al., Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms, Cancer Research, Vol. 52, Issue 12, 1992, pp. 3402-3408	
		YASUAKI et al., 70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity, Journal of Immunology, Vol. 151, No. 10, 1993, pp. 5516-5524	

Examiner Signature	<i>Catharine [Signature]</i>	Date Considered	7/20/04
--------------------	------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/801-988
		Filing Date	03/15/2004
		First Named Inventor	Georges et al.
		Art Unit	1614
		Examiner Name	TBA
Sheet 7 of 9	Attorney Docket Number	112418151/AUR-016	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CJ ↓ ✓		MULTHOFF et al., A Stress-inducible 75-kDa Heat-shock Protein (HSP72) Is Expressed on the Surface of Human Tumor Cells, But Not on Normal Cells, International Journal of Cancer 1995 United States, Vol. 61, no. 2, 1995, pp. 272-279	
		STRIK et al., Heat Shock Protein Expression in Human Gliomas, Anticancer Research 2000 Nov.-Dec. pp. 4457-4462	
		KIANG, et al., Heat Shock Protein 70 kDa, Molecular Biology, Biochemistry, and Physiology, Pharmacology and Therapeutics, Vol. 80, no. 2, November 1998, pp. 183-201	
		VOLM, Manfred, Multidrug Resistance and Its Reversal, Anticancer Research, Vol. 18, no. 4C, July 1998, pp. 2905-2917	
		KURSULA, et al., Structural Determinants for Ligand Binding and Catalysis of Triosephosphate Isomerase, Eur. J. Biochem. 2001, 268, pp. 5189-5196	
		DAVENPORT, et al., Structure of the Triosephosphate Isomerase-Phosphoglycolohydroxamate Complex: An Analogue of the Intermediate on the Reaction Pathway, Biochemistry 1991, 30: pp. 5821-5826	
		ZHANG, et al., Crystal Structure of Recombinant Chicken Triosephosphate Isomerase-Phosphoglycolohydroxamate Complex at 1.8-Å Resolution, Biochemistry 1994, 33: pp. 2830-2837	
		NOBLE, et al., Structures of the "Open" and "Closed" State of Trypanosomal Triosephosphate Isomerase, as Observed in a New Crystal Form: Implications for the Reaction Mechanism, PROTEINS: Structure, Function, and Genetics 1993, 16: 311-326	
		OROSZ, et al., Enhanced Association of Mutant Triosephosphate Isomerase to Red Cell Membranes and to Brain Microtubules, PNAS February 1, 2000, Vol. 97, No. 3, pp. 1026-1031	
	BOYER and MAQUAT, Modulation of Human Triosephosphate Isomerase Gene Transcription by Serum, Journal of Biological Chemistry 1991, Vol. 266, No. 20, pp. 13350-13354		

Examiner Signature	Catherine [Signature]	Date Considered	7/20/04
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/801,988
		Filing Date	03/15/2004
		First Named Inventor	Georges et al.
		Art Unit	1614
		Examiner Name	TBA
Sheet	8	of	9
		Attorney Docket Number	112418.151/AUR-016

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CJ		de BERSAQUES, J., Enzymes of Carbohydrate Metabolism in Human Epidermal Tumors, Journal of Cutaneous Pathology 1975, 2: 198-202	
		NAGASE, et al., Analyses of Polypeptides in the Liver of a Novel Mutant (Lec Rats) to Hereditary Hepatitis and Hepatoma by Two-Dimensional Gel Electrophoresis: Identification of P29/6.8 as Carbonic Anhydrase III and Triosephosphate Isomerase, Comp. Biochem Physiol. 1991, Vol. 99B, No. 1, pp. 193-201	
		ISHIGURO, et al., Identification of Genes Differentially Expressed in B16 Murine Melanoma Sublines with Different Metastatic Potentials, Cancer Research February 15, 1996, 56: 875-879	
		MATSUI, et al., Immobilized pH Gradient Two-Dimensional Gel Electrophoresis and Mass Spectrometric Identification of Cytokine-Regulated Proteins in ME-180 Cervical Carcinoma Cells, Electrophoresis 1997, 18: 409-417	
		KOVÁROVÁ, et al., Proteomics Approach in Classifying the Biochemical Basis of the Anticancer Activity of the New Olomoucine-Derived Synthetic Cyclin-Dependent Kinase Inhibitor, Bohemine, Electrophoresis 2000, 21: 3757-3764	
		RITTER, KLAUS, Affinity Purification of Antibodies from Sera Using Polyvinylidenedifluoride (PVDF) Membranes as Coupling Matrices for Antigens Presented by Autoantibodies to Triosephosphate Isomerase, Journal of Immunological Methods 1991, 137: 209-215	
		CLAUSER, et al., Rapid Mass Spectrometric Peptide Sequencing and Mass Matching for Characterization of Human Melanoma Proteins Isolated by Two-Dimensional PAGE, Proc. Natl. Acad. Sci. May 1995, Vol. 92, pp. 5072-5076	
		MONTGOMERIE, et al., The 28K Protein in Urinary Bladder, Squamous Metaplasia and Urine is Triosephosphate Isomerase, Clinical Biochemistry 1997, Vol. 30, No. 8 pp. 613-18	
✓		LICHTENFELS, et al., Identification of Metabolic Enzymes in Renal Cell Carcinoma Utilizing PROTEOMEX Analyses, Biochimica et Biophysica Acta 2003, 1646: 21-31	
		WANG, et al., Cloning Genes Encoding MHC Class II-Restricted Antigens: Mutated CDC27 as a Tumor Antigen, Science 21 May 1999, Vol. 284, pp. 1351-1354	

Examiner Signature	Cath [Signature]	Date Considered	9/24/04
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/801,988
		Filing Date	03/15/2004
		First Named Inventor	Georges et al
		Art Unit	1614
		Examiner Name	TBA
Sheet 9 of 9	Attorney Docket Number	112418.151/AUR-016	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CD ↓		YIN, et al., Studies of the Proliferation and Differentiation of Immature Myeloid Cells In Vitro: 4: Preculture Proto-Oncogene Expression and the Behaviour of Myeloid Leukemia Cells In Vitro, Cell Biochemistry and Function 1991, Vol. 9, pp. 39-47	
		CHEN, et al., Proteomic Analysis of Lung Adenocarcinoma: Identification of a Highly Expressed Set of Proteins in Tumors, Clinical Cancer Research 2002, Vol. 8, pp. 2298-2305	

Examiner Signature	<i>Catherine [Signature]</i>	Date Considered	7/20/06
--------------------	------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.